The association between Monocyte-to-Lymphocyte ratio and postoperative delirium in ICU patients in cardiac surgery.

OBJECTIVE: To analyze the relationship between monocyte-to-lymphocyte ratio (MLR) and postoperative delirium (POD). METHODS: This cohort study was conducted in the Medical Information Mart for Intensive Care-III (MIMIC-III) version 1.4 database. MLR was measured according to the complete blood count. ICD-9 was used to measure postoperative delirium. Multivariable logistic regression was utilized to examine the relationship between MLR and POD. RESULTS: Three thousand eight hundred sixty-eight patients who had received cardiac surgery were retrospectively enrolled, including 2171 males and 1697 females, with a mean age of 63.9 ± 16.2 years. The univariate analysis suggested that high MLR (as a continuous variable) as associated with a 21% higher risk of POD (O R: 1.12, 95% CI, 1.02, 1.43, p = 0.0259), After adjustments for other confounding factors, gender, age, race, temperature, SBP, DBP, MAP, respiratory rate, SOFA, peripheral vascular disease, AG, psychoses, drug, and alcohol addiction, the results showed that high MLR (as a continuous variable) independently served as a risk factor for POD (OR: 1.21; 95% CI: 1.01-1.44; p = 0.0378). MLR was assessed as quintile and tertiles, high MLR was an independent risk factor for POD. In the subgroup analysis, there were no differences in MLR for patients with POD in pre-specified subgroups. CONCLUSIONS: Monocyte-to-lymphocyte ratio was a risk factor for POD. More research is necessary to thoroughly examine the function of MLR in POD.

Parecoxib mitigates lung ischemia-reperfusion injury in rats by reducing oxidative stress and inflammation and up-regulating HO-1 expression.

PURPOSE: To investigate the protective effect of parecoxib against lung ischemia-reperfusion injury (LIRI) in rats and the mechanism. METHODS: Thirty rats were divided into sham-operated, LIRI and LIRI+parecoxib groups. LIRI model (ischemia for 60 min, followed by reperfusion for 120 min) was constructed in LIRI and LIRI+parecoxib groups. In LIRI+parecoxib group, 10 mg/kg parecoxib was given via femoral vein 15 min before ischemia beginning. At the end of the reperfusion, blood gas analysis, lung wet to dry mass ratio measurement, lung tissue biochemical determination and heme oxygenase-1 (HO-1) protein expression determination were performed. RESULTS: Compared with LIRI group, in LIRI+parecoxib group the oxygenation index was significantly increased, the alveolar-arterial oxygen partial pressure difference was significantly decreased, the lung wet to dry mass ratio was significantly decreased, the lung tissue malondialdehyde content was significantly decreased, the lung tissue superoxide dismutase and myeloperoxidase activities were significantly increased, the lung tissue tumor necrosis factor α and interleukin 1ß levels were significantly decreased, and the lung tissue HO-1 protein expression level was significantly increased (all P < 0.05). CONCLUSIONS: Parecoxib pretreatment can mitigate the LIRI in rats by reducing oxidative stress, inhibiting inflammatory response and up-regulating HO-1 expression in lung tissue.

Derivation and Validation of a Risk Stratification System for Predicting Postoperative Cognitive Impairment.

BACKGROUND: To establish and validate a risk stratification scoring system (we name it as PreOp-BFS, which represents Pre-Operative Brain Fragility Score) for postoperative cognitive impairment containing postoperative cognitive dysfunction (POCD) and postoperative delirium (POD) in elderly patients undergoing non-cardiac surgery. METHODS: We searched for relevant literatures and reviews reported in PubMed and ScienceDirect databases from January 1994 to December 2017. We performed a preoperative risk factor for cognitive impairment in elderly patients (age ≥ 60 years) who underwent non-cardiac surgery, and finally constructed a risk scoring system to predict postoperative cognitive impairment. RESULTS: The test data included 49 patients with postoperative cognitive impairment and 31 patients without postoperative cognitive impairment. The postoperative risk scale score ranged from 0 to 8 points. The incidence of postoperative cognitive impairment was 16.2%, 62.9% and 96.2% in the low (0-2 scores), medium (3-4 scores) and high (5-8 scores) risk groups, respectively. In addition, the risk of postoperative cognitive impairment was significantly higher in high and medium risk groups than in low risk group. Receiver operating characteristic (ROC) analysis showed that the area under the curve (AUC) of the risk scoring system was 0.862 [95% CI 0.784-0.941]. CONCLUSIONS: The preoperative risk stratification scoring system (PreOp-BFS) established in this study had a good prediction effect, which was helpful for rapid identification and screening of high-risk susceptible patients with early postoperative cognitive impairment, and for performing targeted perioperative prevention.

Parecoxib mitigates lung ischemia-reperfusion injury in rats by reducing oxidative stress and inflammation and up-regulating HO-1 expression

ABSTRACT Purpose: To investigate the protective effect of parecoxib against lung ischemia-reperfusion injury (LIRI) in rats and the mechanism. Methods: Thirty rats were divided into sham-operated, LIRI and LIRI+parecoxib groups. LIRI model (ischemia for 60 min, followed by reperfusion for 120 min) was constructed in LIRI and LIRI+parecoxib groups. In LIRI+parecoxib group, 10 mg/kg parecoxib was given via femoral vein 15 min before ischemia beginning. At the end of the reperfusion, blood gas analysis, lung wet to dry mass ratio measurement, lung tissue biochemical determination and heme oxygenase-1 (HO-1) protein expression determination were performed. Results: Compared with LIRI group, in LIRI+parecoxib group the oxygenation index was significantly increased, the alveolar-arterial oxygen partial pressure difference was significantly decreased, the lung wet to dry mass ratio was significantly decreased, the lung tissue malondialdehyde content was significantly decreased, the lung tissue superoxide dismutase and myeloperoxidase activities were significantly increased, the lung tissue tumor necrosis factor α and interleukin 1β levels were significantly decreased, and the lung tissue HO-1 protein expression level was significantly increased (all P < 0.05). Conclusions: Parecoxib pretreatment can mitigate the LIRI in rats by reducing oxidative stress, inhibiting inflammatory response and up-regulating HO-1 expression in lung tissue.